Golden logoGolden logo
Advanced Search
Second Genome

Second Genome

Second Genome is a company that is developing microbiome modulators for infection, immunity and metabolic diseases.

Second Genome is a company that has the mission to redefine disease in terms of microbiome medicine. It uses proprietary microbiome drug discovery and development platform to find effective peptides, proteins and small molecule therapeutics.

Timeline

April 2016
Second Genome raises a $51,000,000 series B round from Digitalis Ventures, LifeForce Capital, Matthew Winkler, Mayo Clinic, Morgenthaler Ventures, Pfizer Venture Investments, Roche Venture Fund, SR One and Seraph Group.
June 5, 2013
Second Genome raises a $11,500,000 series A round from Advanced Technology Ventures and Morgenthaler Ventures.
August 9, 2011
Second Genome raises a $4,999,999 series A round from Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group and Wavepoint Ventures.

Funding Rounds

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Second Genome
June 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight and AI workflows to discover and develop precision...
Second Genome
June 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Second Genome, a tech-enabled biotechnology company that extracts microbial genetic insights to make transformational precision therapies and...
Golden logo
By using this site, you agree to our Terms of Service.